CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Applied Molecular Transport Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Applied Molecular Transport Inc.
450 East Jamie Court
Phone: (650) 392-0420p:650 392-0420 WILMINGTON, DE  19801  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 12/27/2023.
This company ceased filing statements with the SEC on 1/9/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company’s pipeline includes AMT-101, and AMT-126. AMT-101 is a gastrointestinal-selective oral fusion of interleukin 10 (IL-10) and its proprietary carrier molecule that has been designed for active transport across the intestinal epithelium (IE) barrier into local gastrointestinal (GI) tissue. AMT-126 is a GI-selective oral fusion of interleukin 22 (IL-22) and its proprietary carrier molecule presently in development for diseases related to IE barrier function defects. Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Shawn M.Cross 55 3/24/2023 3/1/2020
Chief Financial Officer BrandonHants 46 5/16/2022 1/1/2019
Lead Independent Director HollySchachner 56 5/25/2022 8/23/2021
4 additional Officers and Directors records available in full report.

Business Names
Business Name
AMTI
APPLIED MOLECULAR TRANSPORT

General Information
Number of Employees: 79 (As of 12/31/2022)
Outstanding Shares: 41,848,990 (As of 11/17/2023)
Shareholders: 10
Stock Exchange: NASD
Federal Tax Id: 814481426
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024